Divestiture

Amid a national shortage of over 7M homes, National Equity Fund's record 2025 investments and innovative financing created 14,200 affordable units.

A Pennsylvania court denied class action status in a lawsuit over EtO emissions, a second major legal win for B. Braun that reshapes the litigation landscape.

Medical device firm CVRx is under investigation after its stock nosedived. Did management mislead investors about its salesforce stability?

The eyecare tech firm reports a strong fourth quarter fueled by its TearCare system, even as full-year results show a slight dip. Is this a turning point?

With Vans in a slump and The North Face soaring, VF Corp's new leadership will detail its strategic vision at a key conference watched by Wall Street.

How the chemical giant navigated a complex SAP migration and divestments, using a cloud solution to secure legacy data and cut significant operational costs.

Following a payment default, Crown Castle has terminated its agreement with DISH Wireless, seeking over $3.5 billion for an abandoned network build.

Amid rapid industry consolidation, doctor-owned DSO PepperPointe Partnerships adds three VPs to scale its unique model and support continued expansion.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

As WD-40 leaders prepare for the ICR Conference, investors weigh strong growth plans against a recent earnings miss and a major brand overhaul.

MES Life Safety has offloaded its alleged PFAS liabilities to a third party, a strategic move to de-risk its finances and focus on its core mission.

A major credit upgrade for CABEI reflects a year of smart financial maneuvering, promising cheaper funding for Central America's development projects.

A mysterious new political group has launched a billboard blitz targeting Donald Trump in key battleground districts, signaling an early start to the 2026 wars.

After a major business sale, Elutia is launching NXT-41x, an antibiotic biomatrix designed to combat the high rate of infection in breast reconstruction.

Rigetti Computing pushes back its Cepheus-1-108Q launch to Q1 2026, a move that rattled investors but underscores the quantum industry's tough race for fidelity.

With its first MASH drug a success, Madrigal aims to redefine treatment by combining it with a newly licensed Pfizer asset. Is this the future?

Riding a 50% revenue surge, Rhythm Pharmaceuticals faces a pivotal year with a major FDA decision and key clinical data for its rare obesity treatments.

In a move securing benefits for 400 retirees, Laurentian Bank transfers pension duties, reflecting a wider industry trend to reduce risk and simplify.

Amid a major corporate restructure, Atos partners with the World DanceSport Federation, betting on tech to transform the ballroom and secure its market lead.

With its Q4 earnings approaching, all eyes are on Federal Realty to see if its premium retail strategy can sustain its record dividend amid market shifts.